Mediwound Ltd Net Assets
Mediwound Ltd net assets. Based on the latest financial reports, Mediwound Ltd (MDWD) has net assets worth $59.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.42 Million) and total liabilities ($34.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MDWD shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $59.44 Million |
| % of Total Assets | 62.95% |
| Annual Growth Rate | 5.91% |
| 5-Year Change | 328.4% |
| 10-Year Change | 32.74% |
| Growth Volatility | 109.84 |
Net Assets of Mediwound Ltd (2012–2024)
Net assets of Mediwound Ltd from 2012 to 2024. This chart illustrates how Mediwound Ltd's net assets have evolved over time, based on quarterly financial data. See Mediwound Ltd (MDWD) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Mediwound Ltd (2012–2024)
The table below shows the annual net assets of Mediwound Ltd from 2012 to 2024. For live market cap and overall valuation, see Mediwound Ltd (MDWD) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $31.15 Million | -1.40% |
| 2023-12-31 | $31.59 Million | +189.49% |
| 2022-12-31 | $10.91 Million | +338.19% |
| 2021-12-31 | $-4.58 Million | -163.01% |
| 2020-12-31 | $7.27 Million | -52.06% |
| 2019-12-31 | $15.17 Million | +69.07% |
| 2018-12-31 | $8.97 Million | -6.74% |
| 2017-12-31 | $9.62 Million | +23.81% |
| 2016-12-31 | $7.77 Million | -66.89% |
| 2015-12-31 | $23.47 Million | -45.25% |
| 2014-12-31 | $42.87 Million | +316.48% |
| 2013-12-31 | $-19.80 Million | -226.67% |
| 2012-12-31 | $15.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mediwound Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17298500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Mediwound Ltd Net Assets Breakdown (December 2024)
Mediwound Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $215.00K | 0.69% |
| Other Comprehensive Income | $-11.00K | -0.04% |
| Other Components | $236.00 Million | 757.54% |
| Total Equity | $31.15 Million | 100.00% |
Mediwound Ltd Competitors by Market Cap
The table below lists competitors of Mediwound Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Long Table Growth Corp. Class A Ordinary Shares
NASDAQ:LTGR
|
$171.98 Million |
|
Kolon Corp
KO:002020
|
$171.99 Million |
|
Plano & Plano Desenvolvimento Imobiliário S.A
SA:PLPL3
|
$172.00 Million |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
$172.07 Million |
|
Anhui Yuanchen Environmental Protection Science & Technology Co. Ltd.
SHG:688659
|
$171.85 Million |
|
Texas Ventures Acquisition IV Corp Class A Ordinary Shares
NASDAQ:TVIV
|
$171.81 Million |
|
MK Electron Co. Ltd
KQ:033160
|
$171.69 Million |
|
Readly International AB
ST:READ
|
$171.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mediwound Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,595,000 to 31,153,000, a change of -442,000 (-1.4%).
- Net loss of 30,224,000 reduced equity.
- New share issuances of 22,165,000 increased equity.
- Other comprehensive income increased equity by 7,000.
- Other factors increased equity by 7,610,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.22 Million | -97.02% |
| Share Issuances | $22.16 Million | +71.15% |
| Other Comprehensive Income | $7.00K | +0.02% |
| Other Changes | $7.61 Million | +24.43% |
| Total Change | $- | -1.40% |
Book Value vs Market Value Analysis
This analysis compares Mediwound Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.49x to 4.28x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $5.38 | $13.39 | x |
| 2013-12-31 | $-6.81 | $13.39 | x |
| 2014-12-31 | $15.11 | $13.39 | x |
| 2015-12-31 | $7.58 | $13.39 | x |
| 2016-12-31 | $2.49 | $13.39 | x |
| 2017-12-31 | $2.89 | $13.39 | x |
| 2018-12-31 | $2.32 | $13.39 | x |
| 2019-12-31 | $3.91 | $13.39 | x |
| 2020-12-31 | $1.87 | $13.39 | x |
| 2021-12-31 | $-1.18 | $13.39 | x |
| 2022-12-31 | $2.19 | $13.39 | x |
| 2023-12-31 | $3.51 | $13.39 | x |
| 2024-12-31 | $3.13 | $13.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mediwound Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -149.46%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 2.36x
- Recent ROE (-97.02%) is below the historical average (-72.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 69.98% | 0.00% | 0.00x | 1.63x | $9.38 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.37 Million |
| 2014 | -44.03% | -7287.64% | 0.00x | 1.66x | $-23.16 Million |
| 2015 | -94.11% | -3675.21% | 0.01x | 2.24x | $-24.43 Million |
| 2016 | -243.05% | -1212.13% | 0.04x | 4.60x | $-19.66 Million |
| 2017 | -230.24% | -887.38% | 0.06x | 4.59x | $-23.11 Million |
| 2018 | -11.78% | -31.08% | 0.10x | 3.93x | $-1.95 Million |
| 2019 | 32.67% | 15.59% | 0.78x | 2.68x | $3.44 Million |
| 2020 | -126.46% | -42.26% | 0.70x | 4.27x | $-9.92 Million |
| 2021 | 0.00% | -57.03% | 1.20x | 0.00x | $-13.09 Million |
| 2022 | -179.58% | -73.97% | 0.53x | 4.58x | $-20.69 Million |
| 2023 | -21.26% | -35.94% | 0.28x | 2.10x | $-9.88 Million |
| 2024 | -97.02% | -149.46% | 0.28x | 2.36x | $-33.34 Million |
Industry Comparison
This section compares Mediwound Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mediwound Ltd (MDWD) | $59.44 Million | 69.98% | 0.59x | $171.86 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more